Scarica l'app Stockscreener
4.54
12.19%
-0.63
Dopo l'orario di chiusura:
4.58
0.04
+0.88%
Artelo Biosciences Inc Borsa (ARTL) Ultime notizie
Premarket Movers: GCTK and PFSA Among Gainers, ARTL and BENF Among Losers - ChartMill
Keep an eye on the top gainers and losers in Thursday's session. - ChartMill
Wondering what's happening in today's pre-market session? - ChartMill
Artelo Biosciences (ARTL) Stock Rockets 206% After Obesity Treatment Patent Filing - Blockonomi
Top US Stock Movers for 2026-09-23: VSA Up 135.0%, JAGX Down 73.74% - ChartMill
Let's take a look at the stocks that are in motion in today's session. - ChartMill
After-Hours Movers on September 23, 2026: GCTK and VRME Among Gainers, BENF and BENFW Among Losers - ChartMill
Artelo Biosciences Soars Over 200% on Obesity Drug Patent Filing and Promising Data - finance.biggo.com
Artelo Biosciences (ARTL) Stock Surges Wednesday: What's Happening? - Benzinga
Artelo Biosciences surges after obesity patent filing puts ART27.13 in focus - Quiver Quantitative
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Artelo Biosciences files new provisional patent application covering ART27.13 - TipRanks
Artelo files patent application for obesity treatment ART27.13 - Investing.com
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings - The Manila Times
Artelo Biosciences Files New Provisional Patent Application - GlobeNewswire
Artelo Biosciences reports positive ART27.13 results in neuropathic pain model - scanx.trade
Artelo Biosciences data supports ART26.12 for spinal cord injury pain - scanx.trade
Artelo Cannabinoid Drug Doubles Weight Loss When Paired with Popular Obesity Drug - Benzinga
Artelo Biosciences (ARTL) Reports Promising Weight-Loss Data Ami - GuruFocus
Artelo’s ART27.13 matches semaglutide weight loss in mice study - Investing.com
Artelo Biosciences announces results from nonclinical study of ART27.13 - TipRanks
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity - Yahoo! Finance Canada
Artelo Biosciences at H.C. Wainwright: early data, tight cash By Investing.com - Investing.com South Africa
Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference - ca.finance.yahoo.com
Artelo Biosciences Stock Price Forecast. Should You Buy ARTL? - StockInvest.us
Artelo Biosciences Inc. Warrant (ARTLW) Peer Comparison – Compare with Others - Value Research
Artelo Biosciences Inc. (ARTL) Key Financial Ratios – Valuation, Profitability & More - Value Research
Artelo Biosciences Inc. Warrant (ARTLW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Artelo Biosciences Inc. Warrant (ARTLW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Artelo Biosciences (ARTL) Surges 5.93% as Biotech Speculation IntensifiesFibonacci Retracement - dars.gov.et
Artelo Biosciences Inc. (ARTL) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Artelo Biosciences Inc (NASDAQ: ARTL) Share Price, ARTL Stock News, ARTL Share Price & Updates - kalkine.ca
NeuBase Therapeutics Inc. (NBSE) Peer Comparison – Compare with Others - Value Research
Artelo Biosciences Inc. Warrant (ARTLW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Artelo Biosciences To Carry Out 1-for-9 Reverse Stock Split On August 31st, 2026 - Moomoo
Artelo Biosciences announces 1-for-9 reverse stock split - Investing.com India
Artelo Biosciences (Nasdaq: ARTL) to trade post-split Aug 31 - Stock Titan
Artelo Biosciences announces 1-for-9 reverse stock split By Investing.com - Investing.com Canada
Artelo Biosciences Announces Reverse Stock Split - Barchart.com
Artelo (ARTL) Technicals: Declines 2.86% to $0.69 at the Close; Range View - vinanet.vn
Armistice Capital Exits Artelo Biosciences (ARTL) Position in Co - GuruFocus
Artelo Biosciences wins Japan patent allowance for ART27.13 commercial formulation - Bitget
Artelo Biosciences (ARTL) Secures Japanese Patent for ART27.13, Extending IP Protection to 2041 - GuruFocus
Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 - The Manila Times
Artelo (ARTL) Results at a Glance: The Latest Report Adds New Financial Reference Points at the Close; Share Response: Shares Move 1.25% Up in the Latest ReadingEarnings Preview - vinanet.vn
Artelo Biosciences (ARTL) Q2 2026 Earnings: Clinical-Stage Firm Posts $0.89 Per Share Loss as Shares Fall 8.76%Geographic Revenue Trends - dars.gov.et
Artelo Biosciences (ARTL) Secures Patent Allowance for ART27.13 Commercial Formulation - GuruFocus
Artelo Biosciences Receives a Notice of Allowance from the - GlobeNewswire
ARTL Q2 2026 Earnings: Reported EPS of -$0.89 Reflects Continued Development FocusROIC Trend Report - vinanet.vn
ARTL Q2 2026 Earnings: Reported Loss of -$0.89 Per Share Highlights Clinical-Stage InvestmentGuidance vs Actual - vinanet.vn
Artelo Biosciences (ARTL) major holder reports 0% ownership in new 13G/A - Stock Titan
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):